Baidu
map

J Occup Environ Med:化学和建筑相关不耐受气道炎症性疾病的并发症分析

2017-12-29 AlexYang MedSci原创

最近,有研究人员调查了慢性鼻窦炎、慢性阻塞性肺病、过敏和非过敏哮喘和过敏性鼻炎以及气道炎症症状中的化学不耐受(CI)和建筑相关的不耐受(BRI)并发症。研究人员从2个基于群体的环江健康研究调查问卷中搜集了相关数据。参与者被分成CI或者BRI组和参照组,并且还利用了二维的逻辑回归分析进行了数据分析。研究发现,案例组的疾病患病率为7.2%-40.0%,症状患病率为24.3%-68.9%,调整后的疾病让

最近,有研究人员调查了慢性鼻窦炎、慢性阻塞性肺病、过敏和非过敏哮喘和过敏性鼻炎以及气道炎症症状中的化学不耐受(CI)和建筑相关的不耐受(BRI)并发症。

研究人员从2个基于群体的环江健康研究调查问卷中搜集了相关数据。参与者被分成CI或者BRI组和参照组,并且还利用了二维的逻辑回归分析进行了数据分析。研究发现,案例组的疾病患病率为7.2%-40.0%,症状患病率为24.3%-68.9%,调整后的疾病让步比(ORs)为3.4-26.1、症状的让步比为3.3-17.0,都比参照组要显著更高。患病率和Ors在BRI中要比CI普遍更高。

最后,研究人员指出,炎症气道疾病和症状与CI和BRI相关,并且也促进了阐释相关机制和治疗方法的更进一步的研究。

原始出处:

Claeson AS, Andersson H, Wikdahl F et al. Comorbidity of Airway Inflammatory Diseases in Chemical and Building-Related Intolerance. J Occup Environ Med. 8 Dec 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-05-26 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 july_979
  6. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1736811, encodeId=448a1e36811c4, content=<a href='/topic/show?id=56bf6e024d4' target=_blank style='color:#2F92EE;'>#炎症性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67024, encryptionId=56bf6e024d4, topicName=炎症性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d7334182962, createdName=ms9651749636653578, createdTime=Wed Sep 05 03:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757919, encodeId=a0251e579191c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat May 26 19:33:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Tue Feb 13 06:33:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353062, encodeId=5913135306249, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524251, encodeId=d1721524251c4, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547109, encodeId=c1d1154e109f3, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608392, encodeId=f7ca160839273, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625246, encodeId=443316252466b, content=<a href='/topic/show?id=ab0b638e944' target=_blank style='color:#2F92EE;'>#气道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63879, encryptionId=ab0b638e944, topicName=气道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdc220715535, createdName=3631180, createdTime=Sun Dec 31 11:33:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]

相关资讯

Eur Arch Otorhinolaryngol:环孢霉素鼻喷雾剂在过敏性鼻炎中的效用评估

最近,有研究人员进行了旨在表明是否环孢霉素在小牛血清诱导的过敏性鼻炎小鼠模型中具有抗过敏作用的研究。研究包括了54只小鼠,并被分成6个相同数目的小组。第1组为阴性对照组,没有进行诱导性的过敏性鼻炎;第2小组为阳性对照组,进行了诱导性的过敏性鼻炎但是没有进行治疗。剩下的4个小组在进行过敏性鼻炎诱导之后分别接受了0.05%、0.1%、0.2%浓度剂量的鼻内环孢霉素治疗或者鼻类固醇治疗。在生化检查中,研

J Korean Med Sci:在儿科病人中测量鼻特异性免疫球蛋白E的技术临床评估

目前使用的用于收集鼻特异性免疫球蛋白E(lgE)方法需要大量的生理盐水注入鼻口,这样的操作在儿童中是困难的。最近,有研究人员设计了2种在儿童中使用方便的方法。研究人员测量了鼻特异性lgE,并且评估了在儿科鼻炎患者中鼻特异性lgE的临床特性。研究包括了82名在2014年12月到2016年7月患有鼻炎症状且就诊庆北国立大学儿童医院的病人。30名病人利用喷雾方法,52名病人利用棉拭检验法。研究人员检查了

Mol Med Rep:通过生物信息学方法对鼻炎分子机制的探索

最近,有研究人员分析了基因表达情况来探索差异化表达的基因(DEGs)在鼻炎发病机理中的功能和调控网络,利用的是生物信息学方法。研究人员从基因表达综合数据库中下载了GSE43523基因的表达数据。研究人员的数据集包括了7个季节性鼻炎案例和5个非过敏性正常案例,并通过R limma包分析了鼻炎样本和正常样本之间的DEGs情况。WebGestal数据库用来鉴定DEGs的KEGG信号通路,并利用R中的DC

Asian Pac J Allergy Immunol:哮喘和/或过敏性鼻炎儿童中,大洪水和高空过敏症敏感性分析

洪水也许能够影响气源性致敏原敏化。最近,有研究人员在泰国曼谷2011年大洪水前后,通过皮刺试验(SPT),进行了旨在评估患有哮喘和/或者过敏性鼻炎(AR)儿童气源性致敏原敏化情况的研究。研究分别在2009年和2013年,共在2010名哮喘和/或AR的儿童中进行了SPT试验,结果的阳性率分别为58.2%和60.5%。气源性致敏原的多敏化作用在SPT阳性病人中的67.5%的哮喘病人和67.0%的AR病

Allergy:在游泳运动员中,鼻炎和它对生活品质影响研究

关于游泳运动员也许受鼻炎影响要比普通人群更为明显的数据仍旧有限。鼻炎不仅对游泳运动员能造成生活质量的影响,而且还会影响游泳运动员的表现。最近,有研究人员在游泳运动员和非游泳运动员及对照中,分析比较了鼻炎的流行度和它对QOL影响。研究是一个观察性质的案例对照研究,并且基于调查问卷,包括了101名精英游泳运动员和107名非精英游泳运动员以及38名非游泳运动员,还包括了性别和年龄匹配的50名对照。研究发

Mol Med Rep:二球悬铃木花粉产生的Pla a 2过敏原的表达、纯化和表型分析

悬铃木是户外人类过敏原的主要来源之一,并且能够诱导人类过敏性哮喘、鼻炎、接触性皮肤炎和其他过敏性疾病。Pla a 2是一种聚半乳糖醛酸酶并且在鉴定过的悬铃木木花粉中代表了主要过敏原。最近,有研究人员对Pla a 2进行了表达和春花,并且预测了Pla a 2的B和T细胞表型。研究人员将编码Pla a 2的基因克隆到了Pet28a载体中,随后转化到了DE3大肠杆菌细胞中,并将纯化过的Pla a 2进行

Baidu
map
Baidu
map
Baidu
map